Celsion Company Profile (NASDAQ:CLSN)

About Celsion (NASDAQ:CLSN)

Celsion logoCelsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLSN
  • CUSIP: N/A
  • Web: www.celsion.com
Capitalization:
  • Market Cap: $13.42 million
  • Outstanding Shares: 55,466,000
Average Prices:
  • 50 Day Moving Avg: $0.27
  • 200 Day Moving Avg: $0.42
  • 52 Week Range: $0.19 - $1.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.02
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $500,000.00
  • Price / Sales: 26.12
  • Book Value: $0.11 per share
  • Price / Book: 2.14
Profitability:
  • EBIDTA: ($19,210,000.00)
  • Net Margins: -4,390.50%
  • Return on Equity: -139.38%
  • Return on Assets: -50.47%
Debt:
  • Current Ratio: 0.93%
  • Quick Ratio: 0.93%
Misc:
  • Average Volume: 2.20 million shs.
  • Beta: 1.53
  • Short Ratio: 1.99
 

Frequently Asked Questions for Celsion (NASDAQ:CLSN)

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) released its quarterly earnings results on Thursday, May, 18th. The company reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The company earned $0.13 million during the quarter, compared to analysts' expectations of $0.13 million. Celsion had a negative return on equity of 139.38% and a negative net margin of 4,390.50%. View Celsion's Earnings History.

Where is Celsion's stock going? Where will Celsion's stock price be in 2017?

3 brokers have issued 12 month price targets for Celsion's shares. Their predictions range from $1.50 to $4.00. On average, they expect Celsion's stock price to reach $2.33 in the next twelve months. View Analyst Ratings for Celsion.

What are analysts saying about Celsion stock?

Here are some recent quotes from research analysts about Celsion stock:

  • 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (4/26/2017)
  • 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)

Who are some of Celsion's key competitors?

Who owns Celsion stock?

Celsion's stock is owned by a number of of institutional and retail investors. Top institutional investors include INTRACOASTAL CAPITAL, LLC (5.20%), Renaissance Technologies LLC (2.48%) and Vanguard Group Inc. (1.49%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Egwu, Inc Fka Egen, Inc and Michael H Tardugno. View Institutional Ownership Trends for Celsion.

Who bought Celsion stock? Who is buying Celsion stock?

Celsion's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Vanguard Group Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr and Michael H Tardugno. View Insider Buying and Selling for Celsion.

How do I buy Celsion stock?

Shares of Celsion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Celsion stock cost?

One share of Celsion stock can currently be purchased for approximately $0.24.

Analyst Ratings

Consensus Ratings for Celsion (NASDAQ:CLSN) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $2.33 (890.80% upside)

Analysts' Ratings History for Celsion (NASDAQ:CLSN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
4/10/2017Rodman & RenshawReiterated RatingBuy$1.50HighView Rating Details
4/10/2017HC WainwrightReiterated RatingBuy$1.50HighView Rating Details
11/24/2015Cantor FitzgeraldReiterated RatingNot Available -> BuyN/AView Rating Details
7/13/2015BTIG ResearchInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Celsion (NASDAQ:CLSN)
Earnings by Quarter for Celsion (NASDAQ:CLSN)
Earnings History by Quarter for Celsion (NASDAQ:CLSN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2017Q1 2017($0.09)($0.12)$0.13 million$0.13 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.16)($0.14)$0.13 million$0.13 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.19)($0.23)$0.13 million$0.13 millionViewN/AView Earnings Details
8/15/2016Q2($0.21)($0.19)$0.13 million$0.13 millionViewListenView Earnings Details
5/16/2016Q116($0.21)($0.24)$0.13 million$0.13 millionViewListenView Earnings Details
3/30/2016Q415($0.24)($0.24)$0.16 million$0.13 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.20)$0.14 million$0.13 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.27)$0.16 million$0.13 millionViewListenView Earnings Details
5/12/2015Q1($0.33)($0.34)$0.13 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.36)($0.32)$0.13 million$0.13 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.30)($0.35)$0.16 million$0.13 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.32)$0.13 million$0.13 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.20)($0.33)$0.13 million$0.13 millionViewN/AView Earnings Details
3/13/2014($0.28)($0.19)ViewN/AView Earnings Details
11/12/2013Q3($0.23)($0.30)$0.13 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)$0.01$0.13 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.12)ViewN/AView Earnings Details
11/12/2012Q312($0.17)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celsion (NASDAQ:CLSN)
2017 EPS Consensus Estimate: ($0.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.08)($0.08)($0.08)
Q3 20171($0.03)($0.03)($0.03)
Q4 20171($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celsion (NASDAQ:CLSN)
Insider Ownership Percentage: 7.96%
Institutional Ownership Percentage: 10.74%
Insider Trades by Quarter for Celsion (NASDAQ:CLSN)
Institutional Ownership by Quarter for Celsion (NASDAQ:CLSN)
Insider Trades by Quarter for Celsion (NASDAQ:CLSN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/21/2017Alberto R Martinez JrDirectorBuy35,000$0.23$8,050.00View SEC Filing  
2/15/2017Alberto R Martinez JrDirectorBuy45,000$0.22$9,900.00View SEC Filing  
11/14/2016Alberto R Martinez JrDirectorBuy10,000$0.86$8,600.00View SEC Filing  
11/11/2016Alberto R Martinez JrDirectorBuy10,000$0.91$9,100.00View SEC Filing  
10/7/2016Michael H TardugnoChairmanBuy10,000$1.14$11,400.00View SEC Filing  
8/16/2016Alberto R Martinez JrDirectorBuy5,000$1.25$6,250.00View SEC Filing  
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.00View SEC Filing  
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00View SEC Filing  
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00View SEC Filing  
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00View SEC Filing  
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.00View SEC Filing  
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00View SEC Filing  
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00View SEC Filing  
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.48View SEC Filing  
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.00View SEC Filing  
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.00View SEC Filing  
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.00View SEC Filing  
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.00View SEC Filing  
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.00View SEC Filing  
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.00View SEC Filing  
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.00View SEC Filing  
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.00View SEC Filing  
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00View SEC Filing  
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celsion (NASDAQ:CLSN)
Latest Headlines for Celsion (NASDAQ:CLSN)
Source:
DateHeadline
americanbankingnews.com logoCelsion Co. (CLSN) Announces Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 15 at 11:02 AM
americanbankingnews.com logo$130,000.00 in Sales Expected for Celsion Co. (CLSN) This Quarter
www.americanbankingnews.com - May 14 at 9:15 AM
finance.yahoo.com logoEdited Transcript of CLSN earnings conference call or presentation 12-May-17 3:00pm GMT
finance.yahoo.com - May 13 at 2:56 AM
seekingalpha.com logoCelsion's (CLSN) CEO Michael Tardugno on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:56 PM
americanbankingnews.com logoCelsion Co. (CLSN) Expected to Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - May 12 at 6:20 PM
finance.yahoo.com logoInvestor Network: Celsion Corporation to Host Earnings Call
finance.yahoo.com - May 12 at 4:53 PM
feeds.benzinga.com logoCelsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update
feeds.benzinga.com - May 12 at 8:56 AM
finance.yahoo.com logoCelsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017
finance.yahoo.com - May 5 at 4:34 PM
finance.yahoo.com logoCelsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer Patients
finance.yahoo.com - May 4 at 4:28 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Likely to Affect Celsion (CLSN) Share Price
www.americanbankingnews.com - May 3 at 1:06 AM
americanbankingnews.com logoCelsion (CLSN) Earning Somewhat Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 29 at 12:02 AM
finance.yahoo.com logoETFs with exposure to Celsion Corp. : April 27, 2017
finance.yahoo.com - April 27 at 4:51 PM
americanbankingnews.com logoCelsion Co. (CLSN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 26 at 9:32 PM
americanbankingnews.com logoQ1 2017 Earnings Estimate for Celsion Co. (CLSN) Issued By Griffin Securities
www.americanbankingnews.com - April 26 at 9:09 AM
americanbankingnews.com logoSomewhat Positive News Coverage Somewhat Unlikely to Affect Celsion (CLSN) Share Price
www.americanbankingnews.com - April 25 at 5:09 PM
americanbankingnews.com logoZacks: Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - April 23 at 7:54 AM
americanbankingnews.com logoZacks: Analysts Expect Celsion Co. (CLSN) to Post -$0.14 Earnings Per Share
www.americanbankingnews.com - April 22 at 12:23 AM
streetinsider.com logoCelsion (CLSN) Announces Presentation of OVATION Study Data at ASCO - StreetInsider.com
www.streetinsider.com - April 21 at 9:30 PM
finance.yahoo.com logoCelsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting
finance.yahoo.com - April 20 at 4:29 PM
americanbankingnews.com logoMaxim Group Reaffirms Hold Rating for Celsion Co. (CLSN)
www.americanbankingnews.com - April 20 at 2:04 PM
americanbankingnews.com logoCelsion (CLSN) Receiving Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 20 at 12:19 PM
finance.yahoo.com logoETFs with exposure to Celsion Corp. : April 17, 2017
finance.yahoo.com - April 17 at 4:10 PM
americanbankingnews.com logoCelsion (CLSN) Given Daily News Impact Rating of 0.17
www.americanbankingnews.com - April 17 at 1:47 PM
americanbankingnews.com logoCelsion (CLSN) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - April 14 at 9:31 PM
americanbankingnews.com logoCelsion's (CLSN) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 14 at 7:12 AM
americanbankingnews.com logoShort Interest in Celsion Co. (CLSN) Grows By 83.3%
www.americanbankingnews.com - April 13 at 9:41 AM
finance.yahoo.com logoCelsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia
finance.yahoo.com - April 13 at 9:07 AM
americanbankingnews.com logoCelsion Co. (CLSN) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 10 at 8:46 AM
americanbankingnews.com logoRodman & Renshaw Begins Coverage on Celsion Co. (CLSN)
www.americanbankingnews.com - April 10 at 8:45 AM
finance.yahoo.com logoETFs with exposure to Celsion Corp. : April 5, 2017
finance.yahoo.com - April 7 at 9:02 AM
finance.yahoo.com logoCELSION CORP Financials
finance.yahoo.com - March 30 at 4:47 PM
americanbankingnews.com logoCelsion Co. (CLSN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 8:26 AM
americanbankingnews.com logoCelsion Co. (CLSN) Short Interest Up 399.7% in March
www.americanbankingnews.com - March 26 at 7:17 AM
biz.yahoo.com logoCELSION CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 24 at 9:40 PM
americanbankingnews.com logoCelsion Co. (CLSN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 21 at 8:46 PM
americanbankingnews.com logoCelsion Co. (CLSN) Given “Hold” Rating at Maxim Group
www.americanbankingnews.com - March 18 at 12:10 PM
seekingalpha.com logoCelsion's (CLSN) CEO Michael Tardugno on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 17 at 3:49 PM
finance.yahoo.com logoCelsion Corporation Reports Year End 2016 Financial Results and Provides Business Update
finance.yahoo.com - March 16 at 5:42 PM
biz.yahoo.com logoCELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 16 at 5:42 PM
feeds.benzinga.com logoCelsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017
feeds.benzinga.com - March 9 at 9:25 AM
finance.yahoo.com logoCelsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
finance.yahoo.com - February 27 at 3:42 PM
finance.yahoo.com logo8:35 am Celsion presents two posters on its gen-1 il-12 gene-mediated immunotherapy at the asco-sitc clinical immuno-oncology symposium; OVATION study fully enrolled, final patient enrolled in the fourth cohort
finance.yahoo.com - February 27 at 3:42 PM
finance.yahoo.com logoCelsion Corp. Cancer Medications Insider Buying and Analysis
finance.yahoo.com - February 21 at 3:46 PM
us.rd.yahoo.com logoCelsion Corporation Announces $5.0 Million Public Offering
us.rd.yahoo.com - February 16 at 10:58 AM
biz.yahoo.com logoCELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 16 at 10:58 AM
biz.yahoo.com logoCELSION CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 27 at 5:42 PM
us.rd.yahoo.com logoCelsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
us.rd.yahoo.com - January 19 at 10:36 PM

Social

Celsion (CLSN) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff